Transjugular intrahepatic portosystemic shunt creation for portal hypertension in patients with hepatocellular carcinoma: A systematic review
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: To evaluate the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) creation for the management of portal hypertension in patients with hepatocellular carcinoma (HCC). Methods: A literature search of the MEDLINE/PubMed and Embase databases was conducted. All articles reporting the outcomes of TIPS creation for variceal bleeding and refractory ascites and hepatic hydrothorax in patients with HCC were included. Exclusion criteria were non-English language, sample size < 5, data not extractable, and data reported in another article. Results: A total of 280 patients (mean age, 48–58; male gender, 66%) from five articles were included. TIPS creation was performed for variceal bleeding in 79% and refractory ascites and/or hepatic hydrothorax in 26% of patients. Technical and clinical success was achieved in 99% and 64% of patients, respectively. Clinical failure occurred in 36% of patients due to rebleeding or recurrent bleeding (n = 77) or no resolution or improvement of refractory ascites and hepatic hydrothorax (n = 24). One percent of patient had major complications, including accelerated liver failure (n = 1) and multi-organ failure resulting from hemorrhagic shock (n = 1), all of which resulted in early (i.e., within 30 days) death. Hepatic encephalopathy occurred in 40% of patients after TIPS creation. Lung metastasis was found 1% of patient 5 months (n = 1) and 72 months (n = 1) after TIPS creation. Conclusion: TIPS creation seems to be safe and effective for the management of portal hypertension in patients with HCC.
Abstract
Background: To evaluate the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) creation for the management of portal hypertension in patients with hepatocellular carcinoma (HCC). Methods: A literature search of the MEDLINE/PubMed and Embase databases was conducted. All articles reporting the outcomes of TIPS creation for variceal bleeding and refractory ascites and hepatic hydrothorax in patients with HCC were included. Exclusion criteria were non-English language, sample size < 5, data not extractable, and data reported in another article. Results: A total of 280 patients (mean age, 48–58; male gender, 66%) from five articles were included. TIPS creation was performed for variceal bleeding in 79% and refractory ascites and/or hepatic hydrothorax in 26% of patients. Technical and clinical success was achieved in 99% and 64% of patients, respectively. Clinical failure occurred in 36% of patients due to rebleeding or recurrent bleeding (n = 77) or no resolution or improvement of refractory ascites and hepatic hydrothorax (n = 24). One percent of patient had major complications, including accelerated liver failure (n = 1) and multi-organ failure resulting from hemorrhagic shock (n = 1), all of which resulted in early (i.e., within 30 days) death. Hepatic encephalopathy occurred in 40% of patients after TIPS creation. Lung metastasis was found 1% of patient 5 months (n = 1) and 72 months (n = 1) after TIPS creation. Conclusion: TIPS creation seems to be safe and effective for the management of portal hypertension in patients with HCC.
참고문헌 (26)
- de Franchis R, "Expanding consensus in portal hypertension : report of the baveno vi consensus workshop : stratifying risk and individualizing care for portal hypertension", J Hepatol, 63, pp.743~752 (2015)
- European Association for the Study of the Liver, "EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis", J Hepatol, 53, pp.397~417 (2010)
- Boyer TD, "The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension", Hepatology, 41, pp.386~400 (2005)
- Fattovich G, "Hepatocellular carcinoma in cirrhosis: incidence and risk factors", Gastroenterology, 127(5 Suppl 1), pp.S35~S50 (2004)
- Sakaguchi H, "Combined transjugular intrahepatic portosystemic shunt and segmental lipiodol hepatic artery embolization for the treatment of esophagogastric varices and hepatocellular carcinoma in patients with cirrhosis : preliminary report", Cardiovasc Intervent Radiol, 18, pp.9~15 (1995)
- Liu L, "Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis", Hepatol Res, 44, pp.621~630 (2014)
- Bettinger D, "Efficacy and safety of transjugular intrahepatic portosystemic shunt(TIPPS)in 40 patients with hepatocellular carcinoma", Aliment Pharmacol Ther, 41, pp.126~136 (2015)
- Qiu B, "Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension", World J Gastroenterol, 21, pp.12439~12447 (2015)
- Qiu B, "Transjugular intrahepatic portosystemic shunt for portal hypertension in hepatocellular carcinoma with portal vein tumor thrombus", Cardiovasc Intervent Radiol, 40, pp.1372~1382 (2017)
- Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the prisma statement", Ann Intern Med, 151, pp.264~269 (2009)
- Sacks D, "Society of interventional radiology clinical practice guidelines", J Vasc Interv Radiol, 14, pp.S199~S202 (2003)
- "Quality assessment tool for case series studies"[URL]
- Wallace M, "Transjugular intrahepatic portosystemic shunts through hepatic neoplasms", J Vasc Interv Radiol, 14, pp.501~507 (2003)
- Jiang ZB, "Transjugular intrahepatic portosystemic shunt for palliative treatment of portal hypertension secondary to portal vein tumor thrombosis", World J Gastroenterol, 10, pp.1881~1884 (2004)
- Zhao JB, "Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis", World J Gastroenterol, 20, pp.1602~1607 (2014)
- Dariushnia SR, "Quality improvement guidelines for transjugular intrahepatic portosystemic shunts", J Vasc Interv Radiol, 27, pp.1~7 (2016)
- Cello JP, "Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. a randomized, controlled trial", Ann Intern Med, 126, pp.858~865 (1997)
- Azoulay D, "Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis", J Hepatol, 35, pp.590~597 (2001)
- Monescillo A, "Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding", Hepatology, 40, pp.793~801 (2004)
- Garcia-Pagan JC, "Early use of TIPS in patients with cirrhosis and variceal bleeding", N Engl J Med, 362, pp.2370~2379 (2010)
- Qi X, "Transjugular intrahepatic portosystemic shunt for acute variceal bleeding : a meta-analysis", J Clin Gastroenterol, 49, pp.495~505 (2015)
- Perarnau JM, "Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial", J Hepatol, 60, pp.962~968 (2014)
- Bureau C, "Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts : long-term results of a randomized multicentre study", Liver Int, 27, pp.742~747 (2007)
- Charon JP, "Results of a retrospective multicenter trial of the viatorr expanded polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt creation", J Vasc Interv Radiol, 15, pp.1219~1230 (2004)
- Riggio O, "Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters : results of a randomized controlled trial", J Hepatol, 53, pp.267~272 (2010)
- Qi X, "Covered versus bare stents for transjugular intrahepatic portosystemic shunt : an updated meta-analysis of randomized controlled trials", Therap Adv Gastroenterol, 10, pp.32~41 (2017)